NASDAQ:MYL - Mylan Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $28.69 -0.56 (-1.91 %) (As of 03/24/2019 04:00 PM ET)Previous Close$28.69Today's Range$28.32 - $29.1252-Week Range$26.00 - $42.50Volume5.56 million shsAverage Volume7.87 million shsMarket Capitalization$14.80 billionP/E Ratio6.26Dividend YieldN/ABeta1.47 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Receive MYL News and Ratings via Email Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MYL Previous Symbol CUSIP62853010 CIK1623613 Webwww.mylan.com Phone44-0-17-0785-3000Debt Debt-to-Equity Ratio1.17 Current Ratio1.39 Quick Ratio0.83Price-To-Earnings Trailing P/E Ratio6.26 Forward P/E Ratio6.55 P/E Growth1.21 Sales & Book Value Annual Sales$11.43 billion Price / Sales1.29 Cash Flow$8.6677 per share Price / Cash Flow3.31 Book Value$23.60 per share Price / Book1.22Profitability EPS (Most Recent Fiscal Year)$4.58 Net Income$352.50 million Net Margins3.08% Return on Equity19.06% Return on Assets7.03%Miscellaneous Employees35,000 Outstanding Shares515,950,000Market Cap$14.80 billion Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Mylan (NASDAQ:MYL) Frequently Asked Questions What is Mylan's stock symbol? Mylan trades on the NASDAQ under the ticker symbol "MYL." How were Mylan's earnings last quarter? Mylan NV (NASDAQ:MYL) issued its quarterly earnings data on Tuesday, February, 26th. The company reported $1.30 EPS for the quarter, missing the consensus estimate of $1.36 by $0.06. The company earned $3.04 billion during the quarter, compared to analysts' expectations of $3.10 billion. Mylan had a return on equity of 19.06% and a net margin of 3.08%. The business's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period last year, the company earned $1.43 earnings per share. View Mylan's Earnings History. When is Mylan's next earnings date? Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Mylan. What guidance has Mylan issued on next quarter's earnings? Mylan updated its FY19 earnings guidance on Tuesday, February, 26th. The company provided earnings per share guidance of $3.80-4.80 for the period, compared to the Thomson Reuters consensus estimate of $5.02. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.87 billion.Mylan also updated its FY 2019 guidance to $3.80-4.80 EPS. What price target have analysts set for MYL? 20 Wall Street analysts have issued 1 year target prices for Mylan's shares. Their forecasts range from $31.00 to $59.00. On average, they expect Mylan's stock price to reach $40.7778 in the next twelve months. This suggests a possible upside of 42.1% from the stock's current price. View Analyst Price Targets for Mylan. What is the consensus analysts' recommendation for Mylan? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan. What are Wall Street analysts saying about Mylan stock? Here are some recent quotes from research analysts about Mylan stock: 1. According to Zacks Investment Research, "Mylan’s fourth-quarter results were disappointing as the company missed on both earnings and sales. With the generic market experiencing a slowdown, Mylan itself proactively discontinued a number of products along with transferring some to other sites. These have led to a temporary disruption in supply of certain products and reduced volumes in North America generic sales. The FDA approved rival Teva Pharmaceutical’s generic version of EpiPen and EpiPen Jr, which, in turn, will negatively impact sales further. Moreover, slower-than-expected uptake of generic Copaxone, even after reducing the price by more than 60%, adversely impacted sales in North America. The guidance for 2019 was disappointing as well. Nevertheless, Mylan received a significant boost when the FDA approved its generic version of Advair Diskus — Wixela Inhub — following a few setbacks. Shares have underperformed the industry in the last six months." (3/6/2019) 2. Cantor Fitzgerald analysts commented, "We rate MYL as 12-month price target of $41. We like the company, and there are a lot of potentially positive catalysts coming up. That said, the risk reward is already reflected in the stock’s valuation, in our view. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to calculate our 12- month price target of $41." (11/20/2018) Has Mylan been receiving favorable news coverage? Media stories about MYL stock have trended neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mylan earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near future. Who are some of Mylan's key competitors? Some companies that are related to Mylan include Shire (SHPG), Allergan (AGN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TAK), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF) and Merck KGaA (MKGAF). What other stocks do shareholders of Mylan own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Micron Technology (MU), Starbucks (SBUX), Celgene (CELG), Intel (INTC), General Electric (GE), QUALCOMM (QCOM) and NVIDIA (NVDA). Who are Mylan's key executives? Mylan's management team includes the folowing people: Ms. Heather Bresch, CEO & Exec. Director (Age 50)Mr. Rajiv Malik, Pres & Exec. Director (Age 58)Mr. Kenneth S. Parks, Chief Financial Officer (Age 56)Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 46)Mr. Anthony Mauro, Chief Commercial Officer (Age 46) Who are Mylan's major shareholders? Mylan's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.75%), Pzena Investment Management LLC (4.06%), Bank of New York Mellon Corp (1.92%), Geode Capital Management LLC (1.53%), Norges Bank (1.20%) and Oregon Public Employees Retirement Fund (1.19%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan. Which institutional investors are selling Mylan stock? MYL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Menora Mivtachim Holdings LTD., Carmignac Gestion, Orbimed Advisors LLC, Pzena Investment Management LLC, Bellevue Group AG, Bank of New York Mellon Corp and Millennium Management LLC. View Insider Buying and Selling for Mylan. Which institutional investors are buying Mylan stock? MYL stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Oregon Public Employees Retirement Fund, State of Tennessee Treasury Department, Geode Capital Management LLC, BlackRock Inc., Squarepoint Ops LLC, Toronto Dominion Bank and Dimensional Fund Advisors LP. View Insider Buying and Selling for Mylan. How do I buy shares of Mylan? Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mylan's stock price today? One share of MYL stock can currently be purchased for approximately $28.69. How big of a company is Mylan? Mylan has a market capitalization of $14.80 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe. What is Mylan's official website? The official website for Mylan is http://www.mylan.com. How can I contact Mylan? Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected] MarketBeat Community Rating for Mylan (NASDAQ MYL)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 672 (Vote Outperform)Underperform Votes: 530 (Vote Underperform)Total Votes: 1,202MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/24/2019 by MarketBeat.com StaffFeatured Article: Why is the ex-dividend date different from the record date?